A method for predicting overall survival of patients with leiomyosarcoma Uterine BODY stage I-II

摘要

A method of predicting overall survival of patients with leiomyosarcoma body uterine I-II stage consisting in determining the degree of malignancy of the tumor size and to conduct immunohistochemical determination of expression of the marker Ki 67, characterized in that the determined FIGO stage after hysterectomy with appendages, the degree of malignancy of FNCLCC and additionally performed immunohistochemical study the expression level of BrdU markers, CD31, Topoisomerase IIα, HSP70, study receptor status of the tumor estrogen and progesterone; ploidometriyu; histochemical study nucleolar organizer (AgNORs) tumor cells and the endothelium on the degree of maturity of tumor vessels; determining the density of tumor microvasculature peritumorous zone and calculated predictive value of each parameter with the computation by the formula clinical-morphological and biomolecular indicator (IVM) IVM = X1 + X2 + X3 + X12 ......... where X - is clinical-morphological and biomolecular parameters and characteristics of the investigated parameters and expression values ​​were expressed in points: X-1 (PMTSR) peritumorous zone to 62.4 mm- 2 0 points, a 62.4 mm-in 9 points; X2 - ploidy nuclei to 9.4 with - 0 a 9.4 a - 9 points; X3 - AgNORs number of nuclei to 22.1 - 0 points, more than 22.1 - 3 points; X4 - expression of BrdU to 6.3% - 0 points, more than 6.3% - 3 points; X5 - mature vessels tumors 0 points, immature tumor vessels 3 points; X6 - the degree of malignancy of FNLCC G1 - 0 points, G2 - 2 points, G3 - 3 points; X7 - the reaction HSP70 cytoplasmic, nuclear - cytoplasmic - 0 points, HSP70 nuclear reaction - nucleolar - 3 points; X8 - expression of Ki-67 and 16.2% - 0 points, more than 16.2 % - 3 points; X9 - intensity Topoisomerase II +, ++ - 0 points +++ - 3 points; X10 - p